BridgeBio Oncology Therapeutics
Develops small-molecule therapies for RAS- and PI3K-driven malignancies.
$8.91
After-hours close+0.19 (+2.18%)
At close$8.72(−5.01%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 71.70%57.44M sharesInsiders 0.28%221.8K sharesOther 28.02%22.45M shares
Shares outstanding 80.11M · Float 453.0K · 0.6% free float
A Form 4 total here can count shares the filer formally disclaims — an award voted by proxy, for instance — which the holder's own Schedule 13D/G excludes, so where the two disagree the schedule's smaller figure is used.
Institutions13F, as of Mar 31, 2026
67 holders · 57.44M shares · 23 new positions · 43 increased · 11 reduced · 9 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Cormorant Asset Management, LP | 17.88M | 22.32% | 0 | May 15, 2026 |
| Deerfield Management Company, L.P. (Series C) | 4.89M | 6.10% | 0 | May 15, 2026 |
| Omega Fund Management, LLC | 3.29M | 4.11% | 0 | May 15, 2026 |
| Alphabet Inc. | 2.82M | 3.52% | 0 | May 8, 2026 |
| Ecor1 Capital, LLC | 2.82M | 3.52% | 0 | May 15, 2026 |
| Wellington Management Group LLP | 2.82M | 3.52% | −88.7K | May 15, 2026 |
| Enavate Sciences GP, LLC | 2.63M | 3.28% | 0 | May 15, 2026 |
| Citadel Advisors LLC | 2.53M | 3.16% | −1.6K | May 15, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Bihua Chenincl. Cormorant Private Healthcare Fund III, LP, Cormorant Private Healthcare GP III, LLC +1 more | 31.59% | 7.39M | 13D | Mar 4, 2025 ↗ |
| BridgeBio Pharma LLCincl. BridgeBio Pharma, Inc. | 17.50% | 13.88M | 13D | Aug 18, 2025 ↗ |
| BlackRock Portfolio Management LLC | 7.90% | 1.50M | 13G | Apr 15, 2025 ↗ |
| BC Global Opportunities IX LP | 5.50% | 4.37M | 13G | Sep 3, 2025 ↗ |
| Caisse de dépôt et placement du Québec | 5.26% | Nov 8, 2024 ↗ | ||
| Sculptor Capital LP | 5.12% | 967.5K | 13G | Jul 24, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| BridgeBio Pharma LLC | 10 percent owner | 13.88M | 17.32% | Oct 16, 2025 |
| Pedro Beltran | director, officer: President and CEO | 44.6K | 0.06% | Jul 6, 2026 |
| Yong Ben | officer: Chief Med & Dev Officer | 44.6K | 0.06% | Jul 6, 2026 |
| Albert A. III Holman | other: Former Director | 30.0K | 0.04% | Aug 11, 2025 |
| Mark C. McKenna | other: Former Director | 30.0K | 0.04% | Aug 11, 2025 |
| John P. Schmid | other: Former Director | 30.0K | 0.04% | Aug 11, 2025 |
| Uneek Mehra | other: Former Officer | 22.8K | 0.03% | May 5, 2026 |
| Idan Elmelech | officer: COO & Principal Financial Ofcr | 14.5K | 0.02% | Jul 6, 2026 |
| Marc Cobo | officer: Principal Accounting Officer | 5.3K | 0.01% | Jul 6, 2026 |
1 ten-percent owner holds 13.88M shares by Form 4 — the 13D/G table above shows that stake, the figure above counts officers and directors only
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.